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Available online 4 June 2016Integrin dependent regulation of growth factor signalling confers anchorage dependence that is deregulated in
cancers. Downstream of integrins and oncogenic Ras the small GTPase Ral is a vital mediator of adhesion depen-
dent trafﬁcking and signalling. This study identiﬁes a novel regulatory crosstalk between Ral and Arf6 that con-
trols Ral function in cells. In re-adherent mouse ﬁbroblasts (MEFs) integrin dependent activation of RalA drives
Arf6 activation. Independent of adhesion constitutively active RalA and RalB could both however activate Arf6.
This is further conserved in oncogenic H-Ras containing bladder cancer T24 cells, which express anchorage inde-
pendent active Ral that supports Arf6 activation. Arf6 mediates active Ral-exocyst dependent delivery of raft mi-
crodomains to the plasma membrane that supports anchorage independent growth signalling. Accordingly in
T24 cells the RalB-Arf6 crosstalk is seen to preferentially regulate anchorage independent Erk signalling. Active
Ral we further ﬁnd uses a Ral-RalBP1-ARNO-Arf6 pathway tomediate Arf6 activation. This study hence identiﬁes
Arf6, through this regulatory crosstalk, to be a key downstreammediator of Ral isoform function along adhesion
dependent pathways in normal and cancer cells.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Cancer1. Introduction
Anchorage independent signalling in cancer cells is a key component
of cancer cell invasion and metastasis, reﬂecting the ability of cancer
cells to survive and grow in diverse and otherwise unfavourable envi-
ronments. Cancer metastasis is a major cause of mortality, and thus un-
derstanding the fundamental basis for anchorage dependence and how
it is overcome in cancers is an important problem. In Ras-dependent
cancers, anchorage independence is induced largely through the Ras-
RalGEF-Ral pathway, in which the Ras related GTPases RalA and RalB
are the key mediators [1,2]. Ral GTPases are also activated in Ras-inde-
pendent cancers through other mechanisms [3–5].Ral isoforms, RalA
and RalB, though 82% identical regulate distinct cellular functions in
normal and cancer cells [6–9]. RalA is implicated in driving anchorage
independence [5,10]while RalB supports cell survival in cancers [11].
RalA and RalB bind the same effectors but can signal differently, mediat-
ed by their differential activation [6], utilization of downstream effec-
tors [1]and/or localization in cells [8,12,13].
Anchorage dependence in cells is mediated by integrin-dependent
regulation of cell cycle progression. One key aspect of this regulation ismanian).
. This is an open access article underthe ability of integrinmediated adhesion to control growth factor recep-
tor signalling [14,15]. The trafﬁcking and cellmembrane targeting of raft
microdomains that act as anchoring sites for signallingmolecules on the
plasma membrane is a major mechanism for this regulation [16,17].
Detaching cells from the extracellularmatrix (ECM) triggers rapid endo-
cytosis of thesemicrodomains through caveolae [17], which dramatical-
ly decreases plasmamembrane order [18] and inhibits signalling by Erk,
PI3-kinase and Rho GTPases [16,17,19]. Replating of cells on ECM trig-
gers rapid activation of Arf6 and RalA, which drive the return of these
microdomains to the plasma membrane to restore anchorage depen-
dent signalling [19,20]. Exocytosis of these vesicles is mediated by the
exocyst complex, which both Ral [21–23]and Arf6 [24]bind to. In
mouse ﬁbroblasts, active RalA is necessary and sufﬁcient to drive this
pathway whereas Arf6 is necessary but not sufﬁcient [19,20]. Interest-
ingly, Ral and Arf6 also jointly regulate phospholipase D (PLD) activa-
tion [25,26],GLUT4 receptor trafﬁcking [27–30], insulin secretion [27,
31,32] and Fc-gamma-R mediated phagocytosis [33,34].
These considerations led us to investigate the relationship between
the small GTPases Ral andArf6 in adhesion-dependent signalling in nor-
mal cells and anchorage-independent signalling in Ras transformed
cancer cells. This study identiﬁes a regulatory crosstalk between Ral
and Arf6 that drives their activation downstream of both integrins and
oncogenic Ras. Both active RalA and RalB can support Arf6 activation,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ing this crosstalk and downstream signalling.
2. Results
2.1. RalA regulates adhesion dependent activation of Arf6 in MEFs
Our previous studies showed that RalA andArf6 (but not RalB) activ-
ity decreases on loss of adhesion and recovers upon re-adhesion to ﬁ-
bronectin [19,20]. Active RalA and Arf6 promoted exocyst-dependent
trafﬁcking and plasmamembrane delivery of raft microdomains to sup-
port anchorage dependent signalling [20]. Active Arf6while necessary is
not sufﬁcient for this exocytic delivery while active RalA is necessary
and sufﬁcient [19,20]. To evaluate the possible association between
these GTPases, we measured the activation of each GTPase duringFig. 1. RalA,but not RalB regulates adhesiondependent activationofArf6.Western blot detec
whole cell lysate (WCL) was done from low serum (A) control (CON), RalA knockdown (RalAi)
readherent on ﬁbronectin (FN). (B) Arf6 activity was similarly detected and compared from
(RalAi + hRalA*). (C) Similar western blot detection and quantitation of active RalA pulled d
control (CON) and Arf6 knockdown MEFs (Arf6i). Calculated percentage active Arf6 and RalA
minimum of three and maximum of six independent experiments (as indicated below each gr
and their signiﬁcance represented (* p value b 0.05, ** p value b 0.01 and *** p value b 0.001).integrin-mediated adhesion on siRNA mediated knockdown of the
other. RalA knockdown (Fig. S1A) did not affect the drop in Arf6 activity
on loss of adhesion but prevented its recovery on re-adhesion to ﬁbro-
nectin (Fig. 1A). Reconstitution of RalA knockdown cells with a siRNA
resistantmutant of humanRalA [20] (Fig. S1D) restored normal Arf6 ac-
tivation (Fig. 1B). By contrast, siRNA mediated RalB knockdown (Fig.
S1B) did not affect Arf6 activation (Fig. 1A). Arf6 knockdown (Fig.
S1C) also had no effect on RalA activation (Fig. 1C) suggesting the pres-
ence of an integrin-RalA-Arf6 pathway in MEFs.
2.2. Active Ral supports anchorage independent Arf6 activation and mem-
brane exocytosis
Wenext investigated this pathway in anchorage independent condi-
tions to further evaluate the contribution integrinsmake. Active RalA intion and quantitation of active Arf6 pulled downbyGST-GGA3 (GGA3PD) and total Arf6 in
and RalB knockdown (RalBi) MEFs which were stable adherent (SA), suspended (Susp) or
low serum RalA knockdown MEFs (RalAi) reconstituted with siRNA resistant HA-hRalA*
own by GST-Sec5 (Sec5 PD) and total RalA in whole cell lysate (WCL) from low serum
levels were normalized to respective SA. Graph represents mean ± standard error from a
aph). Statistical analysis of all the data was done using the two tailed single sample t-test
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pendent signalling inmouse ﬁbroblasts [20]. Expression of constitutive-
ly active RalA (RalAV23) in MEFs (Fig. S1E, S1G) induced anchorage
independent Arf6 activation (Fig. 2A) indicating that RalA can mimic
the effect of integrins along this pathway. Interestingly, constitutively
active RalB (RalBV23) also induced anchorage independent Arf6 activa-
tion (Fig. 2B, S1F, S1H). This suggests the presence of a Ral-Arf6 crosstalk
in cells, with a major role for RalA downstream of integrins, a possible
consequence of its differential activation in re-adherent MEFs. It alsoFig. 2. Constitutively active Ral supports anchorage independent Arf6 activation needed for
down byGST-GGA3 (GGA3 PD) and total Arf6 inwhole cell lysate (WCL)was done from low ser
MEFswhichwere stable adherent (SA), suspended (Susp) or readherent on ﬁbronectin (FN). Ca
mean± standard error from aminimum of four and maximum of ﬁve independent experimen
(WB: RalA) (marked by arrow) in control (MEF) and stable shRNA Arf6 expressing MEFs (shAr
bound CTxB-Alexa 594 was imaged (left panel) and intensity quantitated by measuring inte
normalized to their respective controls. Graph is mean ± standard error from 3 such independ
tailed single sample t-test and their signiﬁcance represented (* p value b 0.05 and ** p value
along with the contribution active Ral (RalA*) makes with active Arf6 (Arf6*) (lighter arrow
exocyst complex.establishes active GTP bound Ral as themediator of Arf6 activation, fur-
ther suggesting that this crosstalk could exist downstream of other
stimuli that can activate Ral. We next evaluated the functional signiﬁ-
cance of the Ral-Arf6 crosstalk, by testing its role in the exocyst depen-
dent membrane raft trafﬁcking in non-adherent MEFs [20]. Expression
of the fast cycling RalA (79L) mutant in these cells is seen to promote
anchorage-independent plasmamembrane delivery of GM1 containing
raft microdomains [20]. Stable knockdown of Arf6 (Fig. S1I) while only
modestly affecting total surface GM1 levels (Fig. S1J) did block themembrane raft exocytosis. Western blot detection and quantitation of active Arf6 pulled
umcontrol (CON) and (A) active RalA (RalAV23) and (B) active RalB (RalBV23) expressing
lculated percentage active Arf6 levels were normalized to respective SA. Graph represents
ts (as indicated below each graph). (C) Expression of the FLAG tagged RalA mutant (R79L)
f6). Loss of Arf6 (WB: Arf6) relative to actin (WB: Actin) was conﬁrmed. Cell surface GM1
grated density. Mean integrated density for a minimum of 50 cells was calculated and
ent experiments. (A, B, C) Statistical analysis of normalized data was done using the two
b 0.01). (D) Schematic represents the linear integrin-RalA-Arf6 pathway (bold arrows)
) in mediating the plasma membrane (PM) delivery of raft microdomains through the
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to the plasma membrane in non-adherent MEFs (Fig. 2C). This estab-
lishes a functional role for Arf6 activated downstream of Ral and
hence for this crosstalk in RalA-exocyst mediated membrane raft traf-
ﬁcking. Our earlier studies have shown active Arf6 by itself could not
mediate the complete delivery of raft microdomains at the plasma
membrane [19]. This suggests that along with the linear integrin-Ral-
Arf6 pathway (bolder arrows), RalA works with active Arf6 to deliver
raft microdomains to the plasma membrane (thin arrow), possibly
through the exocyst complex (Fig. 2D). In vitro studies have shown
GST-RalA can bind Arf proteins [35] and they colocalize in lighter mem-
brane raft fractions in H-Ras transformed cells [25,35]. When expressed
in HEK293T cells WT and active RalA and RalB both comparably bound
active T157A Arf6 (Fig. S1K), suggesting their association to not be a di-
rect effector interaction, but possibly mediated by a Ral effector. When
expressed at levels comparable or less than endogenous protein (Fig.
S1M), wild type and active RalA/RalB (V23) also colocalize with active
Arf6 (T157A) in membrane rufﬂes of re-adherent MEFs (Fig. S1L) fur-
ther supporting the plasma membrane to be an active site for this
crosstalk in cells.
2.3. Ral –Arf6 crosstalk in Ras transformed cancers
The Ras-RalGEF-Ral pathway [5,36,37] supports anchorage indepen-
dent Ral activation in cancer [10]. In oncogenic Ras driven cancers, RalA
is the principal determinant of anchorage independent signalling and
growth [5,36,37]whereas RalB is critical for cell survival [11,38,39].
RalB can however also contribute to anchorage independence in some
cancers [40]. We therefore examined the role of RalA and RalB in reg-
ulating Arf6 in K-Ras expressing pancreatic (MiaPaCa2) and H-Ras
expressing bladder (T24) cancer cells [37,41]. We observed anchor-
age independent activation of RalA, RalB (Fig. S2A, S2B, S2C, S2G)
and Arf6, (Fig. 3A and D, S2D) in both cell lines. However, siRNA me-
diated knockdown of RalA and RalB (Fig. S2E, S2F) in MiaPaCa2 cells
did not affect anchorage independent Arf6 activation (Fig. 3B and C).
In T24 cells loss of RalA and RalB (Fig. S2H) did signiﬁcantly and com-
parably reduce (by N50%) anchorage independent Arf6 activity (Fig.
3E). Thus, while both Ral and Arf6 are anchorage-independent in
these cancer cells their regulatory crosstalk is clearly different. In
T24 cells, RalA and RalB act upstream of Arf6 but not in MiaPaCa2
cells.
To further evaluate ability of oncogenic H-Ras to support the Ral-
Arf6 pathway in these cells, we tested and found the expression of
G12V H-Ras in anchorage dependentWTMEFs (Fig. S2J) to promote an-
chorage independent activation of RalA and Arf6 (Fig. 3H). Considering
expression of active RalAV23 is seen to similarly drive anchorage inde-
pendent Arf6 activation in WTMEFs (Fig. 2A), these observations sug-
gest the presence of a H-Ras-Ral-Arf6 pathway.
The above studies looking at the Ral-Arf6 crosstalk in T24 cells (Fig.
3D, E) were done in serum starved (low serum) conditions so that
integrin-mediated adhesion could be observed as the primarymediator
of signalling. Knowing the existence of integrin-growth factor synergies
[14] we further tested this in the presence of serum, aware that anchor-
age independent growth studies implicating Ral in cancers were also
done with serum [37,42]. Detachment of T24 cells in the presence of
serum also showed increased Arf6 activation relative to stable adherent
cells (Fig. 3F). This anchorage-independent Arf6 activity was reduced
signiﬁcantly by loss of RalB but not RalA (Fig. 3G, S2I). This differenceFig. 3. Ral-Arf6 crosstalk in Ras-transformedMiaPaCa2 and T24 cells. (A–C)Western blot de
the respective whole cell lysate (WCL) from MiaPaCa2 cells grown with low serum(A) stable
(RalAi) and (C) suspended control (CON) and RalB knockdown (RalBi). (D–G) Western b
suspended for 120 min (Susp) (D) with low serum and (F) with serum. Similar Active Arf6 l
(RalBi) T24 cells suspended for 120 min (E) with low serum and (G) with serum. (H) West
adherent (SA) and suspended for 120 min (SUS) in the absence (CON) and presence of G12V
were normalized to respective SA/CON. Graphs represent mean ± standard error from a minim
Statistical analysis of normalized data was done using the two tailed single sample t-test and tin regulation between RalA/RalB is not seen in T24 cells with low
serum (Fig. 3E). These results hence support the general conservation
of a H-Ras-Ral-Arf6 pathway in bladder cancer cells but illustrate its
differential regulation by integrins and growth factors. It also suggests
that Ral isoforms in this background can differentially regulate this
crosstalk that could possibly contribute to their differential function in
these cells.
2.4. Role of Ral-Arf6 crosstalk in anchorage independent signalling in
cancers
We hence further explored the role of the RalA/RalB-Arf6 crosstalk
in anchorage independent Erk signalling (Fig. 4A). Active Ral-exocyst
mediatedmembrane raft trafﬁcking in our earlier studies is seen to reg-
ulate anchorage independent Erk activation [20]. To test this regulation
in T24 cells we did both single and joint knockdowns of Ral and Arf6 in
the presence of serum (conﬁrmed in Fig. S3A, S3B, S3C). Erk activation
(Phospho-p44/42 MAPK (Thr202/Tyr204)) in non-adherent T24 cells
was signiﬁcantly reduced by the depletion of Arf6, reﬂecting its role at
the end of the linear H-Ras-Ral-Arf6 pathway. We ﬁnd Erk activation
to be onlymodestly affected by loss of RalA (Fig. 4A), reﬂecting themar-
ginal effect its knockdown has on Arf6 activation in non-adherent T24
cells with serum (Fig. 3G). Their combined knockdown reduced Erk ac-
tivation signiﬁcantly (Fig. 4A) further reﬂecting the role Arf6 has down-
streamof Ral. Interestingly, loss of RalB seen to signiﬁcantly reduce Arf6
activation in suspended T24 cells with serum (Fig. 3G) did signiﬁcantly
affect anchorage independent Erk activation, comparable to its joint
knockdown with Arf6 (RalBi + Arf6i)(Fig. 4A and B, S3). This explains
the differential effect RalB and RalA have on Erk activation in T24 cells,
which is lost on their joint knockdown with Arf6. This could further be
mediated by the differential activation RalB in these cells. In bladder
cancers RalB is reported to be more active than RalA in some studies
[41,43], with a reported role in migration, proliferation and anchorage
independence as well [40,42,44]. In non-adherent T24 cells we tested
and found RalB activity was indeed signiﬁcantly higher than RalA (Fig.
4C). This could mediate its differential utilization of Ral effectors to dif-
ferentially regulate Arf6 activation (Fig. 3G) and anchorage independent
Erk signalling (Fig. 4A).
2.5. Role of Ral effectors in mediating Ral-Arf6 crosstalk
We hence tested the role Ral effectors could have in regulating this
crosstalk by evaluating the role of Sec5 and RalBP1in MEFs and T24
cells. Sec5, a member of the exocyst complex, is known to be involved
in integrin dependent membrane raft trafﬁcking and cell spreading
[20], making it an attractive candidate. Knockdown of Sec5 (Fig. S4A)
did not affect the adhesion dependent activation of Arf6 in re-adherent
MEFs (Fig. 5A). This suggests the role Sec5 has in integrin dependent cell
spreading could be limited to the exocyst complex [20]. The second can-
didate, RalBP1, alongwith being a canonical Ral effector is also reported
to be overexpressed in bladder cancers [41] making it of much interest.
Downstream of R-Ras RalBP1 is also seen to regulate Arf6 activation in-
dependent of Ral [45]. We hence tested its role downstream of Ral in
this pathway. Loss of RalBP1 (Fig. S4B) did not affect the adhesion de-
pendent activation of Arf6, but marginally reduced active Arf6 levels
in non-adherent MEFs (Fig. 5B) (~35% decrease relative to non-adher-
ent control). Interestingly expression of siRNA resistant RalBP1 mutant
in these knockdown MEFs (Fig. S4B, S4C) reversed this drop andtection and quantitation of active Arf6 pulled down by GST-GGA3 (GGA3) and total Arf6 in
adherent (SA) and suspended (Susp), (B) suspended control (CON) and RalA knockdown
lot detection and quantitation of active Arf6 from T24 cells stable adherent (SA) and
evels were determined in control (CON), RalA knockdown (RalAi) and RalB knockdown
ern blot detection and quantitation of active Arf6 and active RalA from WTMEFs stable
H-Ras (H-Ras) with low serum. Calculated percentage active Arf6 levels and RalA levels
um of three and maximum of ﬁve independent experiments as indicated in each graph.
heir signiﬁcance represented (* p value b 0.05, ** p value b 0.01 and *** p value b 0.001).
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(Fig. 5C). To further evaluate its role, RalBP1 was knocked down in
T24 cells using two independent siRNA sequences (Fig. S4D, S4E) and
seen to signiﬁcantly decrease anchorage independent Arf6 activation
in low (Fig. 5D) and with serum conditions (Fig. 5E, F). The effect loss
of RalBP1 has on Arf6 activation was comparable to loss of RalB (Fig.
3G) and their joint knockdown (RalBP1 + RalB) (data not shown) sug-
gesting their effect to be mediated along a common RalB-RalBP1-Arf6
pathway in T24 cells. RalBP1 is known to bind the Arf6 GEF ARNO
(cytohesin-2) to regulate Arf6 activation in mouse ﬁbroblasts [45,46].
Knockdown of ARNO in T24 cells using two independent siRNA se-
quences signiﬁcantly decreased anchorage independent Arf6 activation
(Fig. 5G and H, S4F). Knockdown of cytohesin1 and cytohesin3, seen to
be expressed as well as cytohesin2 (ARNO) in T24 cells (Fig. S4K), did
not affect anchorage independent Arf6 activation (Fig. S4L, S4M) sug-
gesting this regulation of Arf6 to indeed be cytohesin-2 (ARNO) speciﬁc.
RalBP1 and ARNO we also found did not affect anchorage independent
RalA or RalB activation (Fig. S4G, S4H, S4I, S4J) supporting their regula-
tion of Arf6 to be downstream of Ral along a Ral-RalBP1-ARNO-Arf6
pathway in T24 cells.
To conﬁrm this, we tested the effect siRNA mediated knockdown of
RalBP1 and ARNO(Cytohesin-2) have downstreamof active RalA inme-
diating Arf6 activation in WTMEFs (Fig. 2A). In active RalA (RalAV23/
RalA79L) expressing MEFs (Fig. S4N, S4O, S4P) loss of RalBP1 or ARNO
(Fig. S4Q, S4R) signiﬁcantly decreased anchorage independent Arf6 ac-
tivation (Fig. 5I and J) and raft microdomain delivery at the plasma
membrane (Fig. 5K) conﬁrming their role downstream of Ral. Accord-
ingly loss of RalBP1 is also seen to reduce anchorage independent Erk
activation in T24 cells (Fig. 5L). Together this identiﬁes the Ral-
RalBP1-ARNO-Arf6 pathway as a mediator of the Ral-Arf6 crosstalk,
membrane trafﬁcking and signalling (Fig. 5M).
3. Discussion
In deﬁning the regulatory crosstalk between RalA and Arf6 down-
stream of integrins and oncogenic Ras, this study not only reveals the
role Arf6 has downstream of Ral but also how it could help mediate Ral
isoformspeciﬁc function in cells. The differential activation of Ral isoforms
by speciﬁc stimuli we ﬁnd contributes to this crosstalk through the differ-
ential utilization of a Ral effector (RalBP1) with the Arf6 GEF (ARNO).
Downstream of integrins this crosstalk explains the differential role
known for Ral and Arf6 [19,20] in the exocyst complex mediated deliv-
ery of raft microdomains at the plasma membrane. With Ral working
upstream of Arf6 (and not vice versa) targeting Arf6 in an active Ral
background blocks the delivery of raft micrdomains. This reveals Arf6
and this crosstalk to be necessary for Ral-exocyst mediated function
along this pathway [20]. This when considered in context of the fact
that active Arf6 by itself cannot mediated this delivery [19], suggests
the linear integrin-RalA-Arf6 pathway to be further supported by a
role for Ral with active Arf6 in mediating this delivery (Fig. 2D). Such
a joint role could be envisaged as part of the exocyst complex. Spatial ac-
tivation of Arf6 by Ral could facilitate its binding to the exocyst compo-
nent Sec10 allowing for the tethering and delivery of vesicles at the
plasma membrane [24]. Such a localization of Arf6, through its associa-
tion with Rab11 binding FIP3 and FIP4 is seen to recruit the exocyst
complex to the midbody during cytokinesis [47]to which Ral also local-
izes [6]. Arf6 dependent recruitment and activation of PI(4)P 5-kinase
[48] could also generate (PI(4,5)P2) at the plasma membrane [49,50]
that the exocyst component Exo70 can bind [51]. With both integrins
and active Ras localizing at the plasma membrane [52–54], like Ral
and Arf6 do in re-adherent MEFs (Fig. S1L), this could indeed be the
major site where this crosstalk is functional.
While active RalA and RalB can both mediate Arf6 activation, their
differential regulation of this crosstalk downstream of speciﬁc stimuli
could have a role in mediating their isoform speciﬁc function in cells.
This regulation by individual Ral isoforms is directly dependent ontheir differential activation by speciﬁc stimuli. Downstream of integrins
preferential activation of RalA (over RalB) means it drives Arf6 activa-
tion to regulate exocyst function and integrin dependent cell spreading
[20]. Downstreamof oncogenic H-Ras this regulation is further nuanced
by the presence or absence of growth factors. In T24 cells with serum
preferential activation of RalB (over RalA) means it drives Arf6 activa-
tion to differentially regulate anchorage independent Erk signalling in
these cells (Fig. 4A, C, and 3G). RalA with its modest effect on Arf6 acti-
vation affects this pathway only marginally, unless it is targeted with
Arf6. This hence suggests RalA could work as well as RalB along this
pathway, but the preferential activation of RalB and its regulation of
Arf6 makes it the more prominent mediator of Erk signalling [40,42,
44]. In non-adherent WTMEFs as well we ﬁnd RalA and RalB to both
be capable of regulating Arf6 (Fig. 2A and B), though in re-adherent
cells the preferential activation of RalA and its regulation of Arf6 (Fig.
1A) makes it the primary mediator of cell spreading [20].
While Arf6 is not a direct Ral effector, its activation by active Ral does
suggest the possible involvement of a Ral effector(s) in mediating this
crosstalk. RalBP1 we ﬁnd to be such a mediator, regulating anchorage
independent Arf6 activation in active Ral expressing MEFs and T24
cells (Fig. 5E, F and I). However it does not regulate the RalA-Arf6
crosstalk in re-adherent MEFs (Fig. 5B). This suggests the Ral-Arf6
crosstalk while conserved could be regulated differently depending on
the stimulus. Active Ral could mediate the localization of RalBP1, as
seen in the mitochondria [55], to sites of Arf6 activation at the plasma
membrane. This inturn could recruit an Arf6 GEF like ARNO
(cytohesin-2), known to bind RalBP1 [45,56], to the site of Ral and
Arf6 activation. Functionally, RalBP1mediated regulation of Arf6 down-
streamof Ral does affect theplasmamembrane delivery of raftmicrodo-
mains in WTMEFs (Fig. 5K) and anchorage independent Erk signalling
in T24 bladder cancer cells (Fig. 5L).
While this study has focused on understanding the Ral-Arf6 crosstalk
inWTMEFs and bladder cancer T24 cells (expressing H-Ras), we also de-
tected Ral independent activation of Arf6 in pancreatic cancer MiaPaCa2
cells (expressing K-Ras). This hence suggests the crosstalk could be cell
type and/or stimuli speciﬁc. Alternatemechanism(s), such as overexpres-
sion of Arf6 or Arf6 GEFs [57–60] couldmediate Ral independent Arf6 ac-
tivation. The differential association between Ral and Arf6 in H-Ras vs K-
Ras backgrounds, as suggested in their regulation of Phospholipase D1
(PLD1) [25], could further contribute to this difference. It does however
raise the question if this difference in how Arf6 is regulated in these two
cell lines is conserved across other H-Ras and K-Ras dependent cancers.
The contribution Arf6 makes to Ral dependent growth signalling in
these cancers could also be different. Beyond their role inmembrane traf-
ﬁcking and anchorage independent signalling, Ral and Arf6 are involved
in regulating several other cellular pathways including PLD1 activation
[25,26], GLUT4 receptor trafﬁcking [61,62], cellular cytokinesis [6,47], in-
sulin secretion [27,31,32] and Fc-gamma-R mediated phagocytosis [33,
34]. The stimulus speciﬁc nature of the Ral-Arf6 crosstalk, its regulation
and contribution along these pathways will be worth exploring.
4. Materials and methods
4.1. Reagents
Human Plasma ﬁbronectin (Catalog #F2006) and 3X FLAG peptide
(F4799) were procured from Sigma. Cholera toxin subunit B (CTxB) la-
belledwith Alexa 594 (C22843) was fromMolecular Probes and used at
a 1:5000 dilution. Antibodies used include Anti RalA (BD Transduction)
(CLONE 8, Catalog No. 610221) at a 1:2000 dilution [20], Anti RalB (R&D
Biosystems) (catalogNo. AF3204, BatchNo.W1S01) at a 1:1000dilution
[20], Anti Arf6 (gift from Dr. James Casanova) at 1:2000 dilution [19],
Anti-FLAG (Sigma) (Clone M2, Catalog No. F3165, Batch No.
SLBH1191V) at 1:5000 dilution and Anti-FLAG-HRP (Sigma) (Clone
M2, CatalogNo. A8592) at 1:2000 dilution, Antiβ tubulin (Developmen-
tal Studies Hybridoma Bank) (Clone E7, Catalog No. AB_2315513) at
Fig. 4. Ral-Arf6 crosstalk regulates anchorage independent Erk signalling in T24 cells (A)Western blot detection and quantitation of Erk1/2 phosphorylation (P-p44/42MAPK-Thr202/
Tyr204) (WB:pErk) relative to total Erk1/2 (p44/42-MAPK) (WB:Erk) inwhole cell lysates from control (CON), RalA knockdown (RalAi), RalB knockdown (RalBi), Arf6 knockdown (Arf6i),
combined RalA and Arf6 knockdown (RalAi + Arf6i) and combined RalB and Arf6 knockdown (RalBi + Arf6i) T24 cells held in suspension with serum for 120 min. Graph represents
mean ± standard error of the pErk/total Erk band intensity ratios from four independent experiments. Statistical analysis was done comparing knockdown samples to the control
(CON) using the unpaired Students's t-test (* p-value b 0.05). (B) Table consolidates changes in activity of RalA, RalB and Arf6 based on the effect of their respective knockdowns and
crosstalk in the presence of serum (Fig. 4G). Basal activation is represented as ++++ and relative changes indicated accordingly. (C) Graph represents percentage active RalA and
RalB levels in T24 cells suspended with serum from 4 independent experiments (mean ± standard error). This data is analyzed using the unpaired Student's t-test (* p-value b 0.05).
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Catalog No 3630S, batch No. 0001) at 1:1000 dilution [63], Anti pErk1/
2 (P-p44/42 MAPK-Thr202/Tyr204) (Cell Signalling) (Cat# 9101 Lot#
23) at 1:2000 dilution and anti Erk1/2 (p44/42-MAPK) (Cell Signalling)
(Cat # 9102 Lot# 26) at 1:1000 dilution. Anti-β Actin (Abcam)(Clone
ACTN05(C4), Catalog No. ab3280) at 1:2000 dilution, anti Sec5 (N15)
(Santa Cruz Biotechnology) (Clone N-15, Catalog No. sc-30285, Batch
No. D2809) at 1:500dilution [20]and Anti-HA (Roche) (Clone 3F10, Cat-
alog No. 11867423001) at 1:1000 dilution. Published RNA interference
sequences used in this study were procured from Sigma (see supple-
mentary text for detailed listing). SYBR Safe DNA gel stainwas obtained
from Invitrogen (Catalog No. S33102). On-target Plus siRNA smartpool
against mouseSec5 (L-042601), mouseARNO (L-059077) and
humanARNO (L-011925) were from Dharmacon (sequence listing in
supplementary text). FLAG-WT-RalA, FLAG-G23V-RalA, untagged
G23V-RalA, FLAG-G23V-RalB were kind gifts from Dr. Michael White's
lab and pSuper-shArf6-Neo-GFP from Dr. Eunjoon Kim's lab [64]. CFP-
RalA-WT, CFP-RalA-V23, HA-RalB-WT and YFP-RalB-V23 were kind
gifts from Dr. Dan Theodorecu's lab. HA-H-Ras-GV12 was kind gift
from Dr. John Hancock's lab [65].4.2. Tissue culture
Mouse embryonic ﬁbroblasts (MEFs)(from the lab of Dr. Richard An-
derson, University of Texas Health Sciences Center, Dallas TX)were cul-
tured in high glucose DMEMmediumwith 5% fetal bovine serum (FBS).
MiaPaCa2 and T24 cells were procured from ECACC for these studies
and were cultured in RPMI1640 and high glucose DMEM respectively
with 5% FBS. HEK293T cells were procured from ATCC and were cul-
tured in high glucose DMEM with 5% FBS and 1 × PenStrep. Original
vial of cells were grown and frozen down and re-thawed during the
course of experiments. Cells were regularly checked for and found to
be without any bacterial or mycoplasma contamination. Transfections
were done in 6 well plate or 60 mm dishes with 2 μg or 5 μg of plasmid
DNA using the Lipofectamine LTX (Invitrogen) reagent. For knock-
downs, cells seeded in 60 mm dishes were transfected with 100 pmol
duplex siRNA oligo using the RNAiMax transfection reagent
(Invitrogen). This was similarly repeated the next day and cells used
48 hours later. For reconstitutions, rescue vectors were electroporated
(for RalA) (30 μg plasmid +10 μg salmon sperm DNA), or transfected
with LTX (for RalBP1) (12 μg) 24 h after second siRNA transfection,
Fig. 5. Role of Ral Effectors inmediating Ral dependent Arf6 activation. Western blot detection and quantitation of active Arf6 pulled down by GST-GGA3 (GGA3) and total Arf6 in whole
cell lysate (WCL) is represented in the following graphs. (A, B) In low serum control (CON) and (A) Sec5 knockdown (Sec5i) and (B) RalBP1 knockdown (RalBP1i) MEFs which were stable
adherent (SA), suspended (SUSP) or readherent on ﬁbronectin (FN). (C) In siRNA resistant FLAG RalBP1* expressing stable adherent (SA) and suspended (SUSP) RalBP1 knockdown MEFs
(RalBP1i+RalBP1*). (D‐) In suspended control (CON) and RalBP1 knockdown T24 cells (D) targeted with siRNA sequence #1 (RalBP1i #1) in low serum and (E) with siRNA sequence #1
(RalBP1i #1) with serum and (F) sequence #2 (RalBP1i #2) with serum. (G-H). In suspended control (CON) and ARNO knockdown T24 cells targeted with (G) siRNA sequence #1 (ARNOi
#1) with serum and (H) sequence #2 (ARNOi #2) with serum. (I, J) In suspended active Ral (RalAV23) expressing MEFs in low serum (I) with and without RalBP1 (RalV23 + RalBP1i) and
(J) with and without ARNO (RalV23 + ARNOi). Calculated percentage active Arf6 levels were normalized to respective SA/CON/RalAV23. Graphs represent mean ± standard error from a
minimum of three and maximum of ﬁve independent experiments. Statistical analysis was done using the two tailed single sample t-test and their signiﬁcance represented (* p value b 0.05
and ** p value b 0.01). (K) Cell surface GM1 in control (CON) and active RalA mutant expressing WTMEFs (RalA79L) lacking RalBP1 (RalA79L + RalBP1i) or ARNO (RalA79L + ARNOi) was
detected with CTxB-Alexa 594, imaged (top panel) and surface labeling intensity quantitated by measuring integrated density. Integrated density for a minimum of 170 cells was calculated
and mean ± standard error represented in the graph. Graph is representative of two independent experiments that gave similar results. Statistical analysis was done using the two tailed
unpaired t-test and their signiﬁcance represented (* p value b 0.05, ** p value b 0.01, *** p value b 0.001). Signiﬁcance for RalA79L is relative to the CON and for RalA79L + RalBP1i/ARNOi is
relative to RalA79L (L) Western blot detection of Erk phosphorylation (P-p44/42 MAPK-Thr202/Tyr204) (WB:pErk) and total Erk1/2 (p44/42-MAPK) (WB: total Erk) in whole cell lysates
from control (CON) and RalBP1 knockdown (RalBP1i) T24 cells held in suspension with serum for 120 min. Following densitometric scanning band intensity ratio of pErk/total Erk and
RalBP1/Actin were calculated and normalized to control (CON). Blots are representative of two independent experiments that gave similar results. (M) The left panel schematic represents
the RalA-Arf6 pathway in suspended WTMEFs expressing active Ral (RalA*) that through RalBP1 and ARNO drives Arf6 activation (Arf6*) to support the plasma membrane (PM) delivery of
raft microdomains through the exocyst complex. The right panel schematic represents how in T24 cells with serum the H-Ras dependent activation of RalB (RalB*) through RalBP1 and
ARNO drives Arf6 activation (Arf6*) to support anchorage independent Erk signalling.
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lected with G418 (Roche) after transfection with pSuper-shArf6-Neo-
GFP. Serum starvation, suspension and replating of cells was done as
earlier [19,20]. For combined siRNA and plasmid transfections
120 pmol of siRNA and 4 μg of plasmid DNA were transfected using Li-
pofectamine 2000 transfection reagent (Invitrogen) and cells were
used 48 h post transfection.4.3. RNA isolation and RTPCR
Total RNA was isolated using Trizol reagent (Invitrogen) and cDNA
prepared using Reverse Transcriptase and Oligo-dT primers (Promega).
Quantitative PCR done using SYBR FAST qPCR master mix (Kapa
Biosystems) in BioRad CFX96 Real Time System. Primers used are listed
in supplementary text.
Fig. 5 (continued).
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FLAG R79L RalA mutant was made by site-directed mutagenesis of
FLAGWT RalA and FLAG RalBP1* (siRNA insensitive mutant) by site-di-
rected mutagenesis of FLAG WT RalBP1 (gift from the Dr. Lawerence
Goldﬁnger lab). Primers designed using QuikChange tool (Agilent Tech-
nologies) are listed in supplementary text. The siRNA insensitive HA-
RalA* mutant is as described earlier [19,20].4.5. Cell surface labeling with CTxB
MEFs grown in low serum conditions (0.2% serum)were held in sus-
pension labelled and mounted as described earlier [20]. They wereimaged simultaneously using identical setting with a Zeiss LSM 710
laser confocal-Anisotropy microscope with a 40× oil objective and ana-
lyzed using the Image J software (NIH). Thresholds were used to deﬁne
cell edge and create a mask. Total integrated density in cells was mea-
sured and average integrated density calculated.4.6. Arf6 and Ral activity assay
Cells with serum (5% FBS) or low serum (0.2% FBS) were held in sus-
pension (Susp), replated on ﬁbronectin (10 μg/ml) for 15 min (FN) or
stable adherent for 4 h (SA). Cells were lysed and processed for Arf6 ac-
tivity [19] or Ral activity [20] as described earlier. Blots were developed
using the LAS4000 detection system (Fujiﬁlm-GE) and densitometric
1234 A. Pawar et al. / Cellular Signalling 28 (2016) 1225–1236band analysis doneusing Image J software (NIH). Percent active levels of
Arf6 or RalA/RalB were determined by using the following calculation.
Percentage Activity
¼ Pulldown Band Intensity x 100
Corresponding WCL band intensity x Dilution Factor
The dilution factor was calculated as the ratio of the amount of total
cell lysate used for the pulldown (400 μl) and the amount of this lysate
resolved by SDS PAGE in the whole cell lysate (WCL) lane (22.5 μl
WCL + 7.5 μl 4× Lamellis). The dilution factor was hence
400÷ 22.5=17.77. This ratio was kept constant in all our experiments.
Active Arf6 or active RalA levels under different treatment conditions
were normalized to stable adherent (SA) or control (CON).
4.7. Co-immunoprecipitation studies
HEK293T cells transfected with 7 μg of FLAG/FLAG-WT-RalA/FLAG-
G23V-RalA/FLAG-WT-RalB/FLAG-G23V-RalB and 7 μg of HA-T157A-
Arf6 with Lipofectamine LTX reagent for 48 h were lysed (20 mM
HEPES pH 7.5, 400 mM KCl, 5% Glycerol, 5 mM EDTA, 0.4% NP40 + 1X
PIC + phosphatase inhibitors) for 30 min on ice, sonicated and spun
down at 15,000 rpm for 30 min. Lysates (700 μg equivalent) were incu-
bated with Protein G-Dyna beads (Invitrogen) bound to Anti-FLAG
(M2) antibody for 30 min at 4 °C on a rotary mixer in binding buffer
(20 mM HEPES pH 7.5, 50 mM KCl, 5% Glycerol, 5 mM EDTA, 0.05%
NP40+1XPIC+phosphatase inhibitors) [66]. The immune-complexes
were washed and eluted with 200 μg/ml of 3× FLAG peptide. Immuno-
precipitates and whole cell lysates (WCL) were probed with anti-HA
and anti FLAG-HRP antibodies and blots developed using the LAS4000
detection system (Fujiﬁlm-GE).
4.8. Immunoﬂuorescence studies
MEFs transfected with 2 μg of CFP-WT-RalA/CFP-G23V-RalA/HA-
WT-RalB/YFP-V23-RalB and 2 μg of FLAG-T157A-Arf6 using Lipofecta-
mine LTX reagentwere trypsinized, washed and replated on ﬁbronectin
(10 μg/ml) for 15min. Following ﬁxation (3.5% paraformaldehyde) and
permeabilization (PBS containing 0.1% Triton-X-100 - 5min), cells were
blocked with 10% BSA for 30 min at 37 °C, incubated with 1:2000 anti-
FLAG (M2) and anti-HA antibody (Roche) in 3% BSA for 1 h at 37 °C.
Cells were ﬁnally stained with 1:1000 diluted secondary antibody for
1 h at room temperature. All incubations were done in a humidiﬁed
chamber. Stained coverslips were washed and mounted with
Fluoromount-G (Southern Biotech) and imaged using a Zeiss LSM 710
laser confocal-Anisotropy microscope with a 63× oil objective.
4.9. Anchorage independent Erk signalling in T24 cells
T24 cells in 60 mm dishes were treated twice with 50 pmol of each
duplex siRNA oligo (hRalA/hRalB/hArf6-1 + hArf6-2/hRalBP1) or in
combination (hRalA + hArf6-1 + hArf6-2/hRalB + hArf6-1 + hArf6-
2) usingRNAiMax transfection reagent (Invitrogen) as described earlier.
60 h after the second transfection cells were detached held in suspen-
sion for 120 min with 5% serum [20]and then lysed. Cell equivalent
amount of lysates resolved by SDS PAGE and western blotted were
probed with pErk (Thr 202/Tyr 204) and total Erk antibodies. Blots
were developed using chemiluminescent substrates (Pierce) with the
LAS 4000 developing system (Fujiﬁlm-GE). Densitometric analyses of
band intensitieswere doneusing Image J software (NIH) andpErk levels
were normalized to total Erk.
4.10. Statistical analysis
Statistical analysis of data was done using the two tailed unpaired
Student's t-test and when normalized to respective controls using thetwo tailed single sample t-test. All analysis was done using Prism
Graphpad analysis software.
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